CT-202
CNTX-CT202-101
Phase 1 small_molecule active
Quick answer
CT-202 for Triple Negative Breast Cancer (TNBC) is a Phase 1 program (small_molecule) at Context Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Context Therapeutics
- Indication
- Triple Negative Breast Cancer (TNBC)
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- active